Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
ADCs: medicines with the potential to find and kill cancer cells
Antibody-drug conjugates (ADCs) are fast emerging as new cancer treatments, but these smart drugs could soon transform many other areas of medicine too.
More precision, more hope
At the turn of the 20th century, Nobel prize-winning scientist Paul Ehrlich first envisioned a ‘magic bullet’ - a drug that could seek out diseased cells while leaving healthy cells unharmed [1,2]. But it wasn’t until the 1980s that researchers started to use antibodies - proteins that recognize particular molecules on cells - as ‘magic bullets’ to treat cancer. Antibodies are normally produced by the immune system to fight infections. They detect foreign invaders through their unique ‘flags’ called antigens. When scientists realized that tumor cells often had different antigens to healthy cells, they started developing antibody drugs against them, and Ehrlich’s vision began to materialize.
Today there are many antibody drugs used to treat cancer. Yet, although they specifically target cancer cells and can slow or stop their growth, they may not have the same cell-killing firepower as chemotherapy. Scientists are still looking for that magic bullet - a highly potent drug that only exerts its effects on tumor cells. Antibody-drug conjugates (ADCs) could be the answer.
Did you know?
-
11
antibody-drug conjugate drugs now approved [4]
-
>100
conjugates in clinical trials [3]
-
>10
types of cancer now be treated with ADCs [3]
ADCs act on cancer cells
ADCs combine the selectivity of antibodies with the cell-killing power of potent chemotherapies. They comprise a toxic drug chemically attached to an antibody using a linker, which is designed to release the chemical ‘warhead’ exclusively in tumor cells. This allows ADCs to attack cancer cells and - in contrast to chemotherapy drugs alone - spare healthy ones [2].
“This opens up the possibility to use molecules which could never be considered as chemotherapies before, because they caused side effects that were too difficult for the patient to tolerate,” says Carl Deutsch, Director, ADC Chemistry and Biology.
“ADCs provide the ‘best of both worlds’ - the high selectivity of the antibody with the efficacy of the small molecule. You could argue it’s the best way to forge the magic bullet,” he adds.
ADCs are not a new therapeutic concept, but it has taken more than two decades for this promising field to really take off. Between 2019 and 2021, there were seven new approvals for ADC medicines; there are now twelve ADCs approved in the US [3] and eleven approved globally for treating a variety of cancers [4]. For example, ado-trastuzumab emtansine, an ADC drug for breast cancer, combines the anti-HER2 antibody trastuzumab with a chemotherapy drug called DM1. It not only improves survival rates but also reduces the side effects associated with conventional chemotherapy [5].
“Now we are seeing ADCs starting to bring benefits to people with cancer, and we are learning more about them all the time,” says Doreen Koenning, Principal Scientist, ADC Chemistry and Biology, “so we’re always trying to develop every part of the ADC molecule further. This might involve making changes to the antibody molecule or to the linker we use to attach its payload.”
Molecular building blocks
Designing ADCs is a cross-disciplinary effort. The process starts with identifying molecules on the surface of tumor cells - the tumor-associated antigens. Once these have been identified for a specific cancer, scientists try to generate antibodies which bind to them.
“If you have these binders or antibodies in hand, you can start to decide what payload you would like to attach, depending on the disease you want to treat” explains Deutsch. “Then, after linking your antibody to your toxin, you test whether the ADC works on cancer cells in the lab and conduct further engineering of the ADC. This ensures stability in circulation but also effective release of the payload after uptake into tumor cells.”
Constructing each part of an ADC resembles playing with ‘molecular building blocks’ says Koenning, “Engineering the linker, for instance, is one of the very interesting parts of ADC discovery, because it can help you to precisely engineer the release specificity of your ADC.”
When an ADC binds to a cell, it is internalized into the cell and enters a new environment with unique conditions, such as a change in pH or exposure to specific enzymes. “These are factors we can leverage to encourage the toxin to be cleaved from the ADC,” explains Koenning.
Making ADCs even smarter
One potential limitation of ADCs is the finite number of targetable tumor-specific antigens. “Not all antigens that are found in large amounts on tumor cells are unique to tumors. They can also be present on healthy tissue,” says Deutsch. “This means that an ADC targeting such an antigen would have unwanted effects on healthy tissue that could lead to adverse side effects.”
Our scientists are tackling this by using bi-specific antibodies designed to target a combination of two antigens on a tumor cell surface. As they are even more specific to cancer cells, they are extremely unlikely to bind to healthy cells.
“This concept has been used for antibody therapeutics for some time but is pretty new for ADCs. It’s something we are very keen to develop,” says Deutsch. “Our first ADC based on a bi-specific antibody has recently entered clinical testing for solid tumor indications” [6]
Another considerable challenge with ADCs is consistency - ensuring that all the manufactured molecules are identical. “There are several methods for generating ADCs and some of these result in a very heterogeneous product, which can be an issue,” says Koenning. “In addition, it is important to ensure the stability of the resulting ADC, because if the linker releases the drug too soon, this could cause harm to healthy tissues and lead to toxic side effects. Equally, if the linker doesn’t release its drug through the anticipated mode-of-action, the medicine may not be as effective.”
Making ADC development as easy as ABC
In addition to developing our own portfolio of ADCs, we’re providing services and products that help other research teams realize their ADC concepts.
Jyothi Swamy, Head of Process & Technology for APIs, Excipients, Cell Media Technology Cluster explains: “Customers often have an ADC concept in their mind, but they don’t have the infrastructure or resources to take it through the clinic all the way to commercialization. If they have an antibody which is clinically active, they may wish to see how much better it would work if turned into an ADC. They can bring the antibody and any suggestions they have for the payload, and we will make small-scale batches for screening purposes.”
Once a lead candidate has emerged from this process, we can help to further optimize their potential drug by manufacturing clinical trial-grade materials and advising on the testing and Chemistry, Manufacturing and Controls (CMC) requirements for ADCs so that the drug can potentially be taken forward into clinical trials in patients.
“We have worked on more than 70 different ADC constructs in the development space and enabled more than 30 to reach Investigational New Drug status,” says Swamy. “That means we have helped research teams take 30 unique ADCs to patients who didn’t have access to those drugs before.”
In addition to supporting ADCs from discovery to development, our scientists are making it easier for researchers to develop ADCs themselves by providing many of the ingredients to make them, like antibodies, linkers and payloads.
“Recently we have been developing new payload products which are advanced intermediates rather than starting materials. So instead of working on 15-plus synthetic steps, researchers will need four or fewer steps to get to the final product,” explains Swamy.
“I think what makes us unique when it comes to helping others develop ADCs is the breadth of experience and expertise we have. We’ve seen a lot of different types of constructs. When customers bring their concepts or processes to us, we can quickly optimize the process and produce GMP material for their use.”
More precision, more treatments
ADCs have the potential to host a wide range of other useful treatment cargoes. Another approach our scientists are working on for cancer is developing ADCs to help ramp up the response to immunotherapy.
“Immunotherapies are a type of cancer treatment with fewer toxic side effects than conventional chemotherapies. But unfortunately, not all patients respond to these treatments,” says Deutsch. “So our idea is to use an ADC that has a non-toxic, immune-stimulating payload that can potentially help boost a patient’s immune response. If used in combination with other immunotherapies, we hope it would increase the number of patients who respond to this type of treatment.”
ADCs also have the potential to treat autoimmune diseases, such as rheumatoid arthritis or lupus. These diseases are usually treated with broad-acting immuno-suppressant drugs that affect the entire immune system and can have severe side effects. By delivering these drugs only to affected tissues, side effects could potentially be reduced and it may lead to improved quality of life for patients living with these chronic conditions. Antibodies are also being conjugated to dyes to use as therapeutics [7, 8] as well as being linked to short sequences of RNA to target gene therapy to treat some genetic disorders [9].
“I think we are just at the beginning for ADCs,” says Deutsch. “We’ve not even started to focus on some of the opportunities yet, such as how you could use ADCs as a targeting device in infectious diseases, for example, by enabling the use of antibiotics that would otherwise be too toxic.”
“The concept is generic, so there are many areas you can apply it to,” agrees Koenning. “These are complex molecules and there’s a lot to learn, but we’re well equipped to take on the challenge of designing innovative ADCs.”
References
[1] http://smj.sma.org.sg/5111/5111ms1.pdf
[2] https://pubs.acs.org/doi/pdfplus/10.1021/acs.molpharmaceut.5b00302
[3] https://www.biochempeg.com/article/74.html
[4] https://www.oncozine.com/disitamab-vedotin-conditionally-approved-by-chinese-regulator-for-treatment-of-gastric-cancer/ (page 19)
[5] https://news.cancerconnect.com/breast-cancer/kadcyla-t-dm1-significantly-improves-treatment-of-her-2-breast-cancers-7Vqhw73EB0ukbC5NazRjOA
[6] https://www.clinicaltrials.gov/ct2/show/NCT04695847
[7] https://rakuten-med.com/us/illuminox/
[8] https://kodiak.com/
[9] http://www.aviditybiosciences.com/platform/
Work With Us
Is fighting cancer precisely what you want to do?
Do you think the best answer to the question “What did I do all day at work?” is “I helped save lives”? Then join us and become part of our worldwide team. Together we are advancing human progress and finding new cures for diseases like cancer.
View All Jobs Join our Talent Zone